Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | S100A4 | P26447 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557753 | 0.86 | NPC1 (0.73) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL892161 | 0.85 | NPC1 (0.77) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL9834670 | 0.84 | ALDH1A1 (0.59) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL3878827 | 0.83 | NPC1 (0.55) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| Acetic Acid SCHEMBL28745643 | 0.83 | NPC1 (0.69) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL24951909 | 0.82 | MKNK1 (0.45) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL29742828 | 0.82 | MKNK1 (0.45) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL8536799 | 0.81 | NPC1 (0.58) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL8507040 | 0.80 | ALDH1A1 (0.63) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL2665747 | 0.80 | ALDH1A1 (0.61) | NPC1RAB9AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120018406-A | Fine circuit pattern diffusion inhibitor and preparation method and application method thereof | 深圳市板明科技股份有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-120018406-A | Fine circuit pattern diffusion inhibitor and preparation method and application method thereof | 深圳市板明科技股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-2576532-B1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX LLC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9663483-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC | 2016-01-28 | — | — | US | disclosed |
| CN-103108868-B | Furyl compounds and uses thereof | NOVOMEDIX, LLC (US) | 2015-11-25 | — | — | CN | disclosed |
| US-9149527-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| CN-104860907-A | Furanyl compounds and the use thereof | NOVOMEDIX LLC | 2015-08-26 | — | — | CN | disclosed |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-8722731-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2014-05-13 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1688412-A2 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050267149-A1 | Benzoic acid derivatives as modulators of ppar alpha and gamma | ASTRAZENECA AB (SE) | 2005-12-01 | — | — | US | disclosed |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1517680-A1 | BENZOIC ACID DERIVATIVES AS MODULATORS OF PPAR ALPHA AND GAMMA | Astrazeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
| WO-2004000295-A1 | BENZOIC ACID DERIVATIVES AS MODULATORS OF PPAR ALPHA AND GAMMA | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| EP-1361875-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066469-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | NPC1 2440/4885RAB9A 1045/4885ALDH1A1 1575/4885 |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | NPC1 2369/4885RAB9A 916/4885ALDH1A1 1630/4885 |
| US-20050267149-A1 | Benzoic acid derivatives as modulators of ppar alpha and gamma | PPARG, NR4A1, NR0B1 | NPC1 614/4885RAB9A 2897/4885ALDH1A1 1776/4885 |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | NPC1 2440/4885RAB9A 1045/4885ALDH1A1 1575/4885 |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | NPC1 3776/4885RAB9A 609/4885ALDH1A1 2350/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | NPC1 77/4885RAB9A 2845/4885ALDH1A1 1930/4885 |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | NPC1 3776/4885RAB9A 609/4885ALDH1A1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.